Sarepta Therapeutics, Inc. (SRPT) is having another strong day of buying as the company's latest licensing agreement builds an already impressive cash hoard for the company along with other, less-obvious benefits. This follows quickly on the heels of another monumental day for the company as the FDA addressed Sarepta's response to the Complete Response Letter it had sent the company in regard to its clinical candidate, golodirsen (to be known commercially now as Vyondys 53). Sarepta can start commercialization of Vyondys 53 immediately, as it has a commercial setup all in place as